Sign up USA
Proactive Investors - Run By Investors For Investors

Immuron set to commence Clostridium Difficile Infection study in Israel

The company’s IMM-529 is a naturally produced biological antibody product
Immuron set to commence Clostridium Difficile Infection study in Israel
The primary objective of the study is to assess IMM-529's safety and tolerability

Immuron (ASX:IMC, NASDAQ:IMRN) has been granted final approval to begin its first in-human, clinical study for the treatment of C.Difficile Infection (CDI).

CDI is a condition, acute especially in hospitals and in long-term in-patient care facilities due to bacterial toxin causing inflammation of the colon resulting in diarrhoea and in severe cases, death.

This is Immuron's first human clinical study using its IMM-529 product, following the results reported from a series of pre-clinical efficacy studies completed at Monash University.

READ: Immuron targets cash injection

IMM-529 is a naturally produced biological antibody product intended to prevent and treat CDI and designed to spare the gut microbiome from the effects of classic antibiotic treatments.

The new study is to be conducted at the Hadassah Medical Center in Jerusalem. Approval has been granted by the Hadassah Medical Center Ethics Committee and the Israeli Ministry of Health.

Immuron's clinical trial is designed to study a total of 60 patients diagnosed with CDI and have received standard of care antibiotic treatment.

Patients will be enrolled within three weeks of their diagnosis and will be randomised into either IMM-529 three times daily, or placebo, for 28 days.

The primary objective of the study is to assess IMM-529's safety and tolerability.

Immuron’s secondary endpoints are to evaluate the preliminary efficacy of IMM-529 as evaluated by the duration and severity of the symptoms and rate of disease recurrence.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
May 26 2016
Newswire
February 04 2016

Related Articles

GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
Cholesterol gauge
July 25 2017
The assessment of Lojuxta, also known as lomitapide, followed the progress of patients with Homozygous Familial Hypercholesterolaemia
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use